PANTAX study read-out postponed
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the timeline for read-out of the dose-finding clinical Phase Ib study PANTAX will be extended, and read-out is now expected in Q2-Q3 2022. The reasons are challenging patient recruitment and a staggered study design. Disregarding this postponement, the study is performing as well as the Company could have hoped for.In the PANTAX study, Scandion Oncology enrolls patients with unresectable or metastatic pancreatic cancer. The recruitment rate of patients in this very fragile patient population has been lower than